23rd May 2016 11:06
LONDON (Alliance News) - Sareum Holdings said Monday that Phase I trials of its CCT245737 drug candidate are expected to open at the Royal Marsden Hospital in Sutton at the end of May.
Two trials are being conducted in collaboration with co-development partners the CRT Pioneer Fund. One trial is in combination with standard-of-care chemotherapy in lung and pancreatic cancer, whilst the other is as a single anti-cancer agent targeting various cancers.
"We are very pleased to report the anticipated start of the two clinical trials of CCT245737, the first from our development pipeline to be dosed in cancer patients," said Chief Executive Officer Tim Mitchell in a statement.
Shares in Sareum were up 7.2% at 0.949 pence Monday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Sareum